Physician Resources
COVID-19 Vaccine Frequently asked Questions
| Clinical Features |
|
Because of the protean manifestations and relative rarity of the disease, amyloidosis often goes undiagnosed until late in its course. With the development of new therapies, the early diagnosis of amyloidosis offers the possibility of a prolonged remission of this otherwise inexorable disease. Amyloidosis gives rise to a constellation of signs and symptoms but a major clue is the presence of signs or symptoms of disease in multiple organs. |
| Presentations |
| Amyloid Neuropathy – This presentation focuses on the pathogenesis, clinical features, diagnosis, and treatment of peripheral and autonomic neuropathy in patients with amyloidosis. |
| Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide Emerging reports have suggested an increased risk of Second Primary Malignancies (SPM) among Multiple Myeloma patients treated with lenalidomide-based therapy. In this webcast, Dr. Vaishali Sanchorawala discusses results from a post-hoc analysis assessing the rate of SPM among AL amyloidosis patients treated with lenalidomide at Boston Medical Center from 2004-2011. Quick Tips on Nomenclature and Epidemiology on Nomenclature/Epidemiology |